foscarnet and didanosine

foscarnet has been researched along with didanosine in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	12 (54.55)	18.2507
2000's	6 (27.27)	29.6817
2010's	4 (18.18)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S	1
Artursson, P; Bergström, CA; Matsson, P; Nagahara, N; Norinder, U; Tavelin, S	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Ayisi, NK; Gupta, SV; Qualtiere, LF	1
Cersosimo, RJ; Matthews, SJ; Spivack, ML	1
Caliendo, AM; Hirsch, MS	1
Morris, DJ	1
Fleckenstein, B; Stamminger, T	1
Gobert, JM; North, TW; Remington, KM; Zhu, YQ	1
Brun-Vezinet, F; Pépin, JM; Simon, F	1
Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA	1
Cox, S; Harmenberg, J; Palmer, S	1
Alaeus, A; Albert, J; Cox, S; Palmer, S	1

Reviews

6 review(s) available for foscarnet and didanosine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. Pharmacotherapy, 1991, Volume: 11, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine	1991
Combination therapy for infection due to human immunodeficiency virus type 1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 18, Issue:4 Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine	1994
Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug safety, 1994, Volume: 10, Issue:4 Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine	1994
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?]. Pathologie-biologie, 1993, Volume: 41, Issue:8 Pt 2 Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine	1993
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). The American journal of medicine, 1993, Volume: 94, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine	1993

Trials

1 trial(s) available for foscarnet and didanosine

Article	Year
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). The American journal of medicine, 1993, Volume: 94, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine	1993

Article

Year

Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).

The American journal of medicine, 1993, Volume: 94, Issue:2

Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine

1993

Other Studies

16 other study(ies) available for foscarnet and didanosine

Article	Year
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:3 Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine	2000
Exploring the role of different drug transport routes in permeability screening. Journal of medicinal chemistry, 2005, Jan-27, Volume: 48, Issue:2 Topics: Administration, Oral; Biological Transport; Caco-2 Cells; Cell Line; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Membranes, Artificial; Models, Biological; Molecular Conformation; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Pharmacokinetics	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2 Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Didanosine and foscarnet marketed for use by patients with AIDS. Clinical pharmacy, 1992, Volume: 11, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscarnet; Humans; Phosphonoacetic Acid; Retinitis; United States; United States Food and Drug Administration	1992
Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds. Journal of virological methods, 1991, Volume: 33, Issue:3 Topics: Antiviral Agents; Cell Line; Colorimetry; Didanosine; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Tetrazolium Salts; Thymidine; Zalcitabine; Zidovudine	1991
Drugs for AIDS and associated infections. The Medical letter on drugs and therapeutics, 1995, Oct-13, Volume: 37, Issue:959 Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine	1995
[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine]. Fortschritte der Medizin, 1994, May-10, Volume: 112, Issue:13 Topics: AIDS-Related Opportunistic Infections; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Foscarnet; Herpesviridae Infections; HIV Infections; Humans; Zidovudine	1994
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:4 Topics: Animals; Antiviral Agents; Cats; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Foscarnet; Immunodeficiency Virus, Feline; Mutation; Phenotype; Zalcitabine; Zidovudine	1994
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:5 Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Foscarnet; HIV-1; Humans; Microbial Sensitivity Tests; Monocytes; Zalcitabine; Zidovudine	1996
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS research and human retroviruses, 1998, Jan-20, Volume: 14, Issue:2 Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine	1998